“We are very pleased to have initiated our EVERLAST-A study, and we expect nearly all our sites to be open and enrolling by the end of the month,” said Lawrence Klein, CEO of Oruka. “This study could demonstrate three different aspects of ORKA-001’s differentiation – an ultra-long dosing interval, higher efficacy than other IL-23 inhibitors, and the potential for off-treatment remissions. Together with our ORKA-002 program and ORKA-021 sequential combination that are following close behind, we are confident we can have the best biologic regimens in psoriatic disease, an area that continues to reward innovation in biologics.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORKA:
- Oruka Therapeutics: Promising Pipeline and Strategic Advancements Drive Buy Rating
- Strong Buy Recommendation for Oruka Therapeutics: Promising Pipeline and Attractive Valuation
- Positive Outlook for Oruka Therapeutics: ORKA-001’s Promising Phase 2a Trial and Potential Market Differentiation
- Oruka Therapeutics announces IND clearance for EVERLAST-A Phase 2a trial
- Oruka Therapeutics: A Promising Contender in the $30 Billion Psoriasis Market with Innovative Treatments ORKA-001 and ORKA-002